American Pharmaceutical Innovations Company – Trademark Portfolio
Entity Type: 16
American Pharmaceutical Innovations Company holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 6 trademarks are registered. Notable registered marks include AMPHARMA, GLUC-O-BAR, TRIM-O-BAR, and AMERICAN PHARMACEUTICAL INNOVATIONS COMPANY. The owner is based in Downers Grove, IL.
1425 Centre Circle Drive
Downers Grove, IL 60515
Showing of trademarks Trademarks
Trademark Classifications
American Pharmaceutical Innovations Company's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does American Pharmaceutical Innovations Company have?
American Pharmaceutical Innovations Company has 7 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 cancelled.
What trademark classes does American Pharmaceutical Innovations Company file in?
American Pharmaceutical Innovations Company files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are American Pharmaceutical Innovations Company's most well-known trademarks?
American Pharmaceutical Innovations Company's registered trademark portfolio includes well-known marks such as AMPHARMA, GLUC-O-BAR, TRIM-O-BAR, and AMERICAN PHARMACEUTICAL INNOVATIONS COMPANY. These are among 6 currently registered trademarks in the portfolio.
What is American Pharmaceutical Innovations Company's trademark registration success rate?
American Pharmaceutical Innovations Company has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.